Syncom Formulations (India) Limited vs Torrent Pharmaceuticals Limited
A side-by-side comparison of Syncom Formulations (India) Limited (SYNCOMF) and Torrent Pharmaceuticals Limited (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
Syncom Formulations (India) Limited vs Torrent Pharmaceuticals Limited are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.
- Valuation22
- Profitability22
- Growth20
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
SYNCOMF takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 21.4% CAGR over last 5 years", "Company is almost debt free."]
- − []
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 67.6%"]
- − ["Stock is trading at 20.67 times its book value", "Company has a high debt to equity ratio of 1.79."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.